oral semaglutide (Rybelsus)

URI: https://gptkb.org/entity/oral_semaglutide_(Rybelsus)
GPTKB entity
Statements (50)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:activeIngredient gptkb:semaglutide
gptkbp:administrationInstructions take on empty stomach with water
gptkbp:approvalYear 2019
gptkbp:approvedBy gptkb:PMDA
gptkb:FDA
gptkb:EMA
gptkb:Health_Canada
gptkbp:ATCCode gptkb:A10BJ06
gptkbp:brand gptkb:Rybelsus
gptkbp:clinicalTrialPhase PIONEER program
gptkbp:contraindication gptkb:multiple_endocrine_neoplasia_syndrome_type_2
personal or family history of medullary thyroid carcinoma
gptkbp:drugClass GLP-1 receptor agonist
gptkbp:effect promotes weight loss
reduces HbA1c
gptkbp:eliminatedIn urine and feces
gptkbp:firstOralGLP1 true
gptkbp:form gptkb:tablet
14 mg
3 mg
7 mg
gptkbp:halfLife about 1 week
gptkbp:hasBoxedWarning risk of thyroid C-cell tumors
https://www.w3.org/2000/01/rdf-schema#label oral semaglutide (Rybelsus)
gptkbp:indication gptkb:type_2_diabetes
gptkbp:interactsWith may interact with insulin
may interact with other antidiabetic drugs
may interact with sulfonylureas
gptkbp:legalStatus Rx-only
gptkbp:manufacturer gptkb:Novo_Nordisk
gptkbp:marketedIn gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkbp:mechanismOfAction GLP-1 receptor agonist
gptkbp:metabolism proteolytic cleavage
gptkbp:notRecommendedFor gptkb:diabetic_ketoacidosis
type 1 diabetes
gptkbp:pregnancyCategory not recommended
gptkbp:prescriptionStatus prescription only
gptkbp:routeOfAdministration oral
gptkbp:sideEffect nausea
vomiting
diarrhea
abdominal pain
decreased appetite
gptkbp:storage room temperature
gptkbp:bfsParent gptkb:Eligen_technology
gptkbp:bfsLayer 8